Ocular Therapeutix's AXPAXLI Shows Superiority in Wet AMD Trial

Event summary

  • Ocular Therapeutix's AXPAXLI met the primary endpoint in the SOL-1 Phase 3 superiority trial for wet AMD, showing a 17.5% risk difference (p=0.0006) compared to aflibercept at Week 36.
  • 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001) compared to aflibercept.
  • AXPAXLI demonstrated superior and sustained fluid control, with 55.9% of subjects maintaining CSFT within 30 μm from baseline at Week 36.
  • The company plans to submit a New Drug Application (NDA) based on SOL-1 data, subject to planned formal discussions with the U.S. FDA.

The big picture

Ocular Therapeutix's positive SOL-1 trial results position AXPAXLI as a potential game-changer in the wet AMD treatment landscape, offering a novel mechanism and superior durability compared to existing anti-VEGF therapies. The success of this trial could set a new standard for wet AMD treatments, reducing the treatment burden for patients and potentially leading to rapid clinical adoption if approved. The biopharmaceutical industry will be watching closely to see if AXPAXLI can sustain its clinical advantages in real-world settings.

What we're watching

Regulatory Pathway
Whether the FDA will accept the SOL-1 data for a New Drug Application and approve AXPAXLI with a superiority label.
Market Adoption
The pace at which AXPAXLI could gain market share if approved, given its potential to reduce treatment burden and optimize long-term visual outcomes.
Clinical Validation
The outcomes of the SOL-R Phase 3 non-inferiority trial, expected in 1Q 2027, which will further validate AXPAXLI’s durability in a six-month re-dosing paradigm.